PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Current Drug Delivery0 citations

Development of Chitosan Nanoparticles for PRPF31 Gene Delivery in the Treatment of Retinitis Pigmentosa

View Full Paper
MJMd Jobair Hossen JonyEMErik D. MooreADAlekha K. Dash

Key Points

  • The research aims to develop chitosan nanoparticles for effective gene delivery targeting the PRPF31 gene in retinitis pigmentosa.
  • Utilized chitosan as a biocompatible material for nanoparticle formulation.
  • Evaluated the delivery efficacy of pDNA within nanoparticles in vitro.
  • Assessed the potential for non-viral gene therapy applications.
  • Chitosan-pDNA nanoparticles show promise as a delivery vehicle for gene therapy.
  • In vitro studies indicate successful gene delivery efficiency.
  • Further research in animal models is necessary to explore therapeutic potential.

Abstract

These CS-pDNA NPs may have potential as a non-viral delivery vehicle in gene therapy in RP, however, further research in animal models is needed to validate the in vitro findings and for their potential therapeutic applications.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jony et al. (2026) studied this question.

synapsesocial.com/papers/69d895486c1944d70ce062f0https://doi.org/10.2174/0115672018409641251130113502
Ask AI
Helpful
Bookmark
Share
View Full Paper